Orforglipron (Foundayo), as an oral GLP-1, gives Lilly a second incretin franchise that can reach patients who reject injections. A successful oral obesity/diabetes drug would broaden the addressable market and diversify away from sole dependence on tirzepatide.
the thesis · admitted · the reason above is the thesis, not printed twice
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.
the evidence · every sentence checkedthree sentences · whole, uncut
the claims it rests on · in our words, not the filing’s
In the second quarter of 2026, we launched Foundayo (orforglipron) in the U.S. for the treatment of obesity and submitted orforglipron to the FDA for type 2 diabetes